Lantheus Holdings Inc. (NASDAQ:LNTH) reported its financial results for the fourth quarter and full year 2016. It also provided guidance for the current year. The company’s revenue during the fourth quarter stood at 74.4 million, compared to $71.2 million for the fourth quarter of 2015. For the full year 2016, worldwide revenues totaled $301.9 million, compared to $293.5 in 2015. The actual figures exceeded the guidance of $296 million to $299 million.
Lantheus reported its net income for the quarter at $4.9 million or $0.13 per diluted share, compared to $3.9 million or $0.13 per diluted share for the fourth quarter of 2015. Full year 2016 net income totaled $26.8 million, compared to a net loss of $14.7 million in 2015.
The company also provided its projection for 2017 revenue at approximately $312 million to $317 million, compared to $301.9 million in 2016. For the first quarter of 2017, the Company expects worldwide revenues in the range of $77 million to $80 million.
Lantheus also announced inking a new deal with GE Healthcare regarding the continued development of flurpiridaz F 18, an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent.
The company stock has gained over 8 percent this year so far, continuing the robust performance it showed the previous year. Lantheus stock grew over 369 percent in the past 12 months.